Novavax, Inc. - Common Stock (NVAX)
$7.32
0.15 (2.09%)
NVAX Stock Quote Delayed 30 Minutes
Novavax Stock Can Rally, But It’s Still Facing Many Obstacles
Novavax's vaccine will likely be approved by the FDA relatively soon, but NVAX stock is still facing many obstacles.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
545.22M
PE Ratio
-3.20
EPS
-2.29
Volume (Avg. Vol.)
3.93M
Day's Range
$7.17 - $7.42
52-Week Range
$3.81 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax, Inc. - Common Stock News
NVAX Stock Alert: 14 Things to Know as the Novavax Vaccine Faces the FDA Today
Novavax (NVAX) stock is in the news today as investors prepare for the results from the vaccine company's meeting with the FDA.
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning
Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine.
Let the Market’s Shakeout Finish Before Buying Novavax Stock
Even after the company's first profitable quarter, it's still too early to accumulate NVAX stock as an analyst issues a bearish price target.
Avoid Novavax Stock as Its Hopes Dwindle
The FDA approval is the only hope for Novavax. If you own it, hold NVAX stock until the approval but do not take a new position right now.
NVAX Stock Falls 20% as Novavax Misses Q1 Estimates
The drug maker's stock is falling sharply on news that the company missed the profit and revenue expectations of analysts.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! We're starting off another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!
Novavax Stock Is Too Sickly To Buy
Any hope that pharmaceutical company Novavax will gain widespread approval to bring a Covid-19 vaccine to market is now over.
Why Is Novavax Stock Rising This Week?
The quarterly results and FDA approval for EUA could push NVAX stock higher in the coming weeks, so take your position now.
The Window of Opportunity Has Closed for Novavax
A series of missteps left Novavax far behind in the vaccine race. Continued delays and roadblocks continue to hurt NVAX stock.
Dear Novavax (NVAX) Stock Fans, Mark Your Calendars for June 7
NVAX stock is in the green after the FDA announced it would meet on June 7 to discuss the company's emergency use authorization request.
Novavax Stock Is Now Speculative, But it Still Has a Shot
NVAX stock has become speculative, but it still has multiple ways to win. The company needs to step up its marketing game.
Novavax Could Get Analyst Downgrades Leading Up to Earnings
Novavax recently got Nuvaxovid approved for use in Japan for both primary and booster shots. It’s done nothing for NVAX stock.
Novavax Stock Could Give Back More of Its Pandemic-Era Gains
While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium.
Novavax Stock Looks Like a Good Value With Its New Combined Vaccine
NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.
Is Novavax a Buy After Its Vaccine Approval in Switzerland?
Novavax is late to the Covid-19 vaccine race and is up against some stiff competition. NVAX stock is in a tough spot.
What Volatility in Novavax Means for Investors
Novavax continues to await FDA news about its Covid-19 vaccine, but that's not everything that drives the price of NVAX stock.
The Longer the Wait, The Smaller the Opportunity for Novavax
The delay in FDA approval is making the opportunity smaller for Novavax, but the opportunity still remains. NVAX stock is a hold.
